Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
>
Procedures
>
Therapeutic or Preventive Procedure
>
Electroconvulsive Therapy
Electroconvulsive Therapy
Electroconvulsive Therapy (ECT) is a medical procedure that involves the administration of controlled electric currents to the brain, inducing a seizure.
It is primarily used to treat severe mental health conditions, such as major depressive disorder, bipolar disorder, and treatment-resistant schizophrenia.
PubCompare.ai's AI-powered platform helps researchers and clinicians locate the latest ECT protocols from literature, preprints, and patents, while using intelligent comparisons to identify the best protocols and products.
This streamlines the research process and optimizes outcomes, enabling advancements in this important field of mental health treatment.
It is primarily used to treat severe mental health conditions, such as major depressive disorder, bipolar disorder, and treatment-resistant schizophrenia.
PubCompare.ai's AI-powered platform helps researchers and clinicians locate the latest ECT protocols from literature, preprints, and patents, while using intelligent comparisons to identify the best protocols and products.
This streamlines the research process and optimizes outcomes, enabling advancements in this important field of mental health treatment.
Most cited protocols related to «Electroconvulsive Therapy»
Brain
Cerebrovascular Accident
Congenital Abnormality
Cortex, Cerebral
Electroconvulsive Therapy
Motor Cortex
Multiple Sclerosis
Muscle Rigidity
Neoplasms
Neuronavigation
Patients
Safety
Scalp
Seizures
Therapeutics
Tissues
Transcranial Magnetic Stimulation, Repetitive
Chloride, Lithium
Electroconvulsive Therapy
Food
Foot
Helplessness, Learned
Hunger
Institutional Animal Care and Use Committees
Males
Mice, House
Mice, hr
Motivation
Retinal Cone
Shock
T-Lymphocyte
In the present analysis we have focussed on the following clinician-administrated rating scales:
The Hamilton Depression Scale (HAM-D17) in combination with the Melancholia Scale (MES) with a scoring sheet [16 , 17 ] in which a Visual Analogue Scale for Depression Severity (VAS) is placed at the bottom as a horizontal line from 0 (no depression) to 100 mm (extreme depression). The interviewer is asked to score the VAS before completing the HAM-D17 and MES. The LEAD procedure (Longitudinal Expert Assessment of All Data) was thus used to make the global severity assessment of depressive states taking into account all available data over the past three days.
As discussed elsewhere [17 ] the horizontal version (yard stick-line) with descriptive cues at each end and 100 mm in between is generally preferred.
The LEAD principle was used to clinically validate the HAM-D17 [13 ] which resulted in that six of the Hamilton items (depressed mood, guilt feelings, work and interests, psychomotor retardation, psychic anxiety, and general somatics (fatigability)), HAM-D6, were found to be most valid when associated with experienced psychiatrists’ global assessment of depression severity. The Bech-Rafaelsen Melancholia Scale (MES) was developed to capture the six HAM-D6 core items with reference to the Cronholm-Ottosson Depression Scale [21 ]. For a review of the MES, see [22 ].
The three depression symptom rating scales (HAM-D17, HAM-D6, MES) were rated on a weekly basis by KM and ML, as was the VAS, using the time frame of the past three days for the VAS as well. The MDI was also completed each week by the patients. The clinicians (KM, ML) had no access to the MDI scorings. The inter-rater reliability of KM and ML as Danish University Antidepressant Group (DUAG) raters has been found acceptable with intraclass coefficients of 0.89 (HAM-D6), 0.93 (HAM-D17) and 0.91 (MES) [Martiny et al.: Relapse prevention in major depressive disorder: A four-arm randomised 6-month double-blind comparison of three fixed dosages of escitalopram and a fixed dose of nortriptyline in patients successfully treated with acute electroconvulsive treatment (DUAG-7) – Submitted 2015].
The Hamilton Depression Scale (HAM-D17) in combination with the Melancholia Scale (MES) with a scoring sheet [16 , 17 ] in which a Visual Analogue Scale for Depression Severity (VAS) is placed at the bottom as a horizontal line from 0 (no depression) to 100 mm (extreme depression). The interviewer is asked to score the VAS before completing the HAM-D17 and MES. The LEAD procedure (Longitudinal Expert Assessment of All Data) was thus used to make the global severity assessment of depressive states taking into account all available data over the past three days.
As discussed elsewhere [17 ] the horizontal version (yard stick-line) with descriptive cues at each end and 100 mm in between is generally preferred.
The LEAD principle was used to clinically validate the HAM-D17 [13 ] which resulted in that six of the Hamilton items (depressed mood, guilt feelings, work and interests, psychomotor retardation, psychic anxiety, and general somatics (fatigability)), HAM-D6, were found to be most valid when associated with experienced psychiatrists’ global assessment of depression severity. The Bech-Rafaelsen Melancholia Scale (MES) was developed to capture the six HAM-D6 core items with reference to the Cronholm-Ottosson Depression Scale [21 ]. For a review of the MES, see [22 ].
The three depression symptom rating scales (HAM-D17, HAM-D6, MES) were rated on a weekly basis by KM and ML, as was the VAS, using the time frame of the past three days for the VAS as well. The MDI was also completed each week by the patients. The clinicians (KM, ML) had no access to the MDI scorings. The inter-rater reliability of KM and ML as Danish University Antidepressant Group (DUAG) raters has been found acceptable with intraclass coefficients of 0.89 (HAM-D6), 0.93 (HAM-D17) and 0.91 (MES) [Martiny et al.: Relapse prevention in major depressive disorder: A four-arm randomised 6-month double-blind comparison of three fixed dosages of escitalopram and a fixed dose of nortriptyline in patients successfully treated with acute electroconvulsive treatment (DUAG-7) – Submitted 2015].
Full text: Click here
Antidepressive Agents
Anxiety
Depressive Symptoms
Diploid Cell
Electroconvulsive Therapy
Escitalopram
Feelings
Guilt
Interviewers
Major Depressive Disorder
Melancholia
Mood
Nortriptyline
Patients
Psychiatrist
Reading Frames
Relapse Prevention
Visual Analog Pain Scale
Animals
Anxiety
Corticotropin-Releasing Hormone
Darkness
Electricity
Electroconvulsive Therapy
Fear
Homo sapiens
Hormones
Light
Neoplasm Metastasis
Nervousness
Nucleus, Central Amygdaloid
Nucleus of Stria Terminalis
Rattus
Reflex, Startle
Shock
Walkers
Eleven consecutive patients with severe, chronic TRD were enrolled in a research protocol at Emory University testing safety and efficacy of SCC DBS for TRD (clinicaltrials.gov NCT00367003). Participants provided written informed consent to participate. The protocol was approved by the Emory University Institutional Review Board and the US Food and Drug Administration under an Investigational Device Exemption (G060028 held by H.S.M.) and is monitored by the Emory University Department of Psychiatry and Behavioral Sciences Data and Safety Monitoring Board.
The inclusion and exclusion criteria were essentially identical to those previously published by Holtzheimer et al. describing the first seventeen subjects implanted at Emory University (15 (link)). Key inclusion criteria consisted of: 18 to 70 years-old with a diagnosis of major depressive disorder (confirmed with the Structured Clinical Interview for DSM-IV and by the study psychiatrists (PRP, SJG, PEH, ALC)); a current depressive episode of at least 12 months without significant response to at least 4 adequate antidepressant treatments (scoring 3 or higher on the Antidepressant Treatment History Form and verified through medical records); lifetime failure or intolerance of electroconvulsive therapy or inability to receive electroconvulsive therapy; average score ≥ 20 on the 17-item Hamilton Depression Rating Scale (HDRS-17) averaged over the four weeks prior to surgery; Global Assessment of Functioning (GAF) of 50 or less; capacity to provide informed consent; and being able to relocate to the Atlanta area for 7 months (26 –29 ).
Key exclusion criteria were defined as: clinically significant medical or psychiatric comorbidity (including personality disorders as determined by a review of medical records, the Structured Clinical Interview-II, and clinical examination); active substance use disorder; active suicidal ideation with plan or intent, a suicide attempt within the past 6 months, or more than 2 suicide attempts within the past 2 years; pregnancy or planning to become pregnant during the study; or contraindication for DBS surgery or chronic stimulation.
The preoperative evaluation lasted a minimum of 4 weeks. Chronic stimulation was initiated 4 weeks following surgery. Outcome was assessed weekly for 24 weeks of active stimulation using the HDRS-17. Response to treatment was defined as at least a 50% decrease and remission as 7 points or less on the HDRS-17 at 24 weeks. For any missing timepoint the previous observation was carried forward to the next timepoint. Medication changes were not allowed during the preoperative evaluation phase or the initial 24 weeks of chronic DBS. All patients received cognitive behavioral therapy. Patients were aware that they were receiving active stimulation, but were not privy to the criteria for target identification, contact selection or dose increases. All procedures were carried out at Emory University.
The inclusion and exclusion criteria were essentially identical to those previously published by Holtzheimer et al. describing the first seventeen subjects implanted at Emory University (15 (link)). Key inclusion criteria consisted of: 18 to 70 years-old with a diagnosis of major depressive disorder (confirmed with the Structured Clinical Interview for DSM-IV and by the study psychiatrists (PRP, SJG, PEH, ALC)); a current depressive episode of at least 12 months without significant response to at least 4 adequate antidepressant treatments (scoring 3 or higher on the Antidepressant Treatment History Form and verified through medical records); lifetime failure or intolerance of electroconvulsive therapy or inability to receive electroconvulsive therapy; average score ≥ 20 on the 17-item Hamilton Depression Rating Scale (HDRS-17) averaged over the four weeks prior to surgery; Global Assessment of Functioning (GAF) of 50 or less; capacity to provide informed consent; and being able to relocate to the Atlanta area for 7 months (26 –29 ).
Key exclusion criteria were defined as: clinically significant medical or psychiatric comorbidity (including personality disorders as determined by a review of medical records, the Structured Clinical Interview-II, and clinical examination); active substance use disorder; active suicidal ideation with plan or intent, a suicide attempt within the past 6 months, or more than 2 suicide attempts within the past 2 years; pregnancy or planning to become pregnant during the study; or contraindication for DBS surgery or chronic stimulation.
The preoperative evaluation lasted a minimum of 4 weeks. Chronic stimulation was initiated 4 weeks following surgery. Outcome was assessed weekly for 24 weeks of active stimulation using the HDRS-17. Response to treatment was defined as at least a 50% decrease and remission as 7 points or less on the HDRS-17 at 24 weeks. For any missing timepoint the previous observation was carried forward to the next timepoint. Medication changes were not allowed during the preoperative evaluation phase or the initial 24 weeks of chronic DBS. All patients received cognitive behavioral therapy. Patients were aware that they were receiving active stimulation, but were not privy to the criteria for target identification, contact selection or dose increases. All procedures were carried out at Emory University.
Antidepressive Agents
ARID1A protein, human
Barakat syndrome
Clinical Trials Data Monitoring Committees
Cognitive Therapy
Diagnosis
Electroconvulsive Therapy
Ethics Committees, Research
Major Depressive Disorder
Medical Devices
Operative Surgical Procedures
Patients
Personality Disorders
Pharmaceutical Preparations
Physical Examination
Pregnancy
Psychiatrist
Safety
Substance Use Disorders
Suicide Attempt
Most recents protocols related to «Electroconvulsive Therapy»
The study took place in the second year of a three-year Bachelor of Nursing programme at a Norwegian university. This undergraduate nursing education programme entailed 180 credits in the European Credit Transfer and Accumulation System (ECTS) [34 ]. More specifically, the nursing students got 90 ECTS credits from theoretical courses mainly in the academic setting, minimum 75 ECTS credits from clinical placement in a variety of settings, and maximum 15 ECTS credits from simulation-based education in laboratories [34 ]. The study was conducted in two learning settings: a simulation centre on the university campus and an acute care hospital unit.
In the simulation setting, the students took part in a two-day simulation-based education course comprising six simulation sessions focusing on different deteriorated patient conditions and diagnoses. Nine faculty members were involved as facilitators and operators. Students were divided into groups of six to nine, alternating between the roles of nurse and observer. The simulation environment mirrored a patient room in a hospital unit and Laerdal SimMan 3G™ and ALS™ manikins were used. Each simulation session (90 min) consisted of a prebriefing (15 min), a simulated scenario (15 min), a viewing of the video recording of the simulated scenario (15 min), and a facilitator-led group debriefing (45 min). For the debriefing, the Promoting Excellence and Reflection in Simulation (PEARLS) structured and scripted debriefing [35 (link)] method was used.
After the simulation-based education course, the students attended an eight-week clinical placement course in a medical or surgical hospital unit hosting adult patients with acute, critical, and chronic conditions. Students provided nursing care under the supervision of a registered nurse working in the relevant unit. Nurse educators supervised the students in groups to promote reflection and learning and to evaluate their learning outcomes.
The learning outcomes for both courses entailed the same clinical judgment skills.
In the simulation setting, the students took part in a two-day simulation-based education course comprising six simulation sessions focusing on different deteriorated patient conditions and diagnoses. Nine faculty members were involved as facilitators and operators. Students were divided into groups of six to nine, alternating between the roles of nurse and observer. The simulation environment mirrored a patient room in a hospital unit and Laerdal SimMan 3G™ and ALS™ manikins were used. Each simulation session (90 min) consisted of a prebriefing (15 min), a simulated scenario (15 min), a viewing of the video recording of the simulated scenario (15 min), and a facilitator-led group debriefing (45 min). For the debriefing, the Promoting Excellence and Reflection in Simulation (PEARLS) structured and scripted debriefing [35 (link)] method was used.
After the simulation-based education course, the students attended an eight-week clinical placement course in a medical or surgical hospital unit hosting adult patients with acute, critical, and chronic conditions. Students provided nursing care under the supervision of a registered nurse working in the relevant unit. Nurse educators supervised the students in groups to promote reflection and learning and to evaluate their learning outcomes.
The learning outcomes for both courses entailed the same clinical judgment skills.
Full text: Click here
Adult
Chronic Condition
Diagnosis
Education, Nursing, Baccalaureate
Electroconvulsive Therapy
Europeans
Faculty
Faculty, Nursing
Managed Care
Nursing Care
Operative Surgical Procedures
Patients
Reflex
Registered Nurse
Student
Students, Nursing
Supervision
The study was approved by the ethics review committee of Yu Quan Hospital, and written informed consent was obtained from all participants prior to the commencement of the study. Patients with MDD were recruited from inpatient departments of Yu Quan Hospital from September 2013 to August 2016. The diagnoses of all patients were established by the Structured Clinical Interview according to the DSM-IVTR (SCID). Exclusion criteria include: 1) age less than 18 or over 60 years; 2) left-handed which is evaluated by Edinburgh handedness inventory; 3) major physical illnesses such as malignant tumor, chronic renal failure, severe heart disease, and severe respiratory disease; 4) other psychiatric disorders and neurological disorders; 5) substance abuse; 6) took medication within the 3-month period prior to the study; and 7) received electroconvulsive therapy. Finally, 40 patients were include in the present study. Twenty-three right-handed healthy controls (HC) were recruited from the local community by advertisements. Age, gender and educational level were matched between MDD groups and HC. The control subjects were screened using the non-patient edition of the SCID to confirm the lifetime absence of a history of psychiatric or neurological disorders and were interviewed to exclude family history of psychiatric illness.
Diagnosis
Electroconvulsive Therapy
Gender
Heart Diseases
Inpatient
Kidney Failure, Chronic
Malignant Neoplasms
Mental Disorders
Nervous System Disorder
Patients
Pharmaceutical Preparations
Physical Examination
Respiration Disorders
SCID Mice
Substance Abuse
Participants were aged 18 years or older, with a diagnosis of MDD by DSM-IV criteria and failure to respond to at least one adequate antidepressant treatment. Major exclusion criteria included: current treatment with electroconvulsive therapy; dementia, intellectual disability, or psychosis; current use of illicit drugs; and cardiovascular decompensation. Subjects were on oral antidepressant treatment and did not have to discontinue current medications, which should remain unchanged from 15 days before intervention until the end of the follow-up period.
Full text: Click here
Administration, Oral
Antidepressive Agents
Cardiovascular System
Diagnosis
Electroconvulsive Therapy
Illicit Drugs
Intellectual Disability
Pharmaceutical Preparations
Presenile Dementia
Psychotic Disorders
Therapeutics
The LIFT-MOOD study was conducted at St. Michael's Hospital, Unity Health Toronto. Recruitment began in June 2021, with randomization completed by February 2022. All participants were outpatients screened for study eligibility at the Centre for Depression and Suicide Studies at St. Michael's Hospital. Participants were included if they were between 18 and 65 years of age, had a diagnosis of MDD without psychotic features according to the Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition criteria, were in a major depressive episode as confirmed by the Mini International Neuropsychiatric Interview,26 (link) and had a score of 18 or greater on the Hamilton Depression Rating Scale (HAMD).27 (link) According to the definition of TRD, all participants had to have failed at least 2 trials of antidepressant therapy of an adequate dose and duration during the current depressive episode.28 (link) Data regarding antidepressant history and current medication use were collected using the Antidepressant Treatment History Form.29 Participants were required to maintain their current antidepressant regimen 28 days before the screening visit and during the study. Highly effective or double-barrier contraceptive methods were used for women of childbearing potential.
Participants presenting with comorbidity of neuropsychological disorders (eg, PTSD, dementia) or with a diagnosis of depression secondary to medical illnesses were excluded. Participants were also excluded if they presented with acute suicidality or underwent electroconvulsive therapy within the current depressive episode. The full list of inclusion and exclusion criteria is presented inSupplemental Materials (Table S1) . A research coordinator carried out all screening assessments. The Research Ethics Board of St. Michael's Hospital, Unity Health Toronto, approved the study (20-301). The trial is registered at http://clinicaltrials.gov (NCT04727229). All participants provided written informed consent after fully reviewing the study protocol and prior to participating.
Participants presenting with comorbidity of neuropsychological disorders (eg, PTSD, dementia) or with a diagnosis of depression secondary to medical illnesses were excluded. Participants were also excluded if they presented with acute suicidality or underwent electroconvulsive therapy within the current depressive episode. The full list of inclusion and exclusion criteria is presented in
Antidepressive Agents
Contraception, Barrier
Dementia
Diagnosis
Electroconvulsive Therapy
Eligibility Determination
Mental Disorders
Mood
Outpatients
Pharmaceutical Preparations
Post-Traumatic Stress Disorder
Treatment Protocols
Woman
Patient data regarding psychosis and VTE were extracted from the hospital medical record system. Psychosis-related information included disease type, the Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD), and treatments administered including restraint, artificial hibernation, antipsychotic, antidepressant, and electroconvulsive therapy (ECT). VTE-based information included thrombus distribution. We obtained demographic data regarding admission and investigated the approximate incidence of each mental illness and the clinical features of VTE, including VTE distribution in the left and right extremities and venous involvement. Based on the site of thrombosis, patients with VTE were categorized into proximal and distal DVT groups, and we performed intergroup comparison of characteristics and risk factors for mental illnesses. Patients with VTE were further categorized into PE and non-PE groups based on detection of PE. We also performed intergroup comparison of types of mental illnesses and mental disorder scores.
Antidepressive Agents
Antipsychotic Agents
Anxiety
Electroconvulsive Therapy
Hibernation, Artificial
Mental Disorders
Patients
Psychotic Disorders
Thrombosis
Thrombus
Veins
Top products related to «Electroconvulsive Therapy»
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in Italy
The Model 7800 is a precision instrument used for the measurement of physical parameters. It is designed to provide accurate and reliable data collection for scientific research and laboratory applications.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
Sourced in United States, Germany, United Kingdom, France, Switzerland, Canada, Japan, Australia, China, Belgium, Italy, Denmark, Spain, Austria, Netherlands, Sweden, Ireland, New Zealand, Israel, Gabon, India, Poland, Argentina, Macao, Finland, Hungary, Brazil, Slovenia, Sao Tome and Principe, Singapore, Holy See (Vatican City State)
GlutaMAX is a chemically defined, L-glutamine substitute for cell culture media. It is a stable source of L-glutamine that does not degrade over time like L-glutamine. GlutaMAX helps maintain consistent cell growth and performance in cell culture applications.
Sourced in United States, Germany, United Kingdom, China, Italy, Japan, France, Sao Tome and Principe, Canada, Macao, Spain, Switzerland, Australia, India, Israel, Belgium, Poland, Sweden, Denmark, Ireland, Hungary, Netherlands, Czechia, Brazil, Austria, Singapore, Portugal, Panama, Chile, Senegal, Morocco, Slovenia, New Zealand, Finland, Thailand, Uruguay, Argentina, Saudi Arabia, Romania, Greece, Mexico
Bovine serum albumin (BSA) is a common laboratory reagent derived from bovine blood plasma. It is a protein that serves as a stabilizer and blocking agent in various biochemical and immunological applications. BSA is widely used to maintain the activity and solubility of enzymes, proteins, and other biomolecules in experimental settings.
Sourced in United States, United Kingdom, Germany, New Zealand, Japan, China, France, Australia, Italy, Spain, Switzerland, Canada, Netherlands, Denmark, Austria, Belgium, Ireland, Israel, Brazil
Horse serum is a biological fluid derived from the blood of horses. It contains a complex mixture of proteins, including immunoglobulins, hormones, and other biomolecules. Horse serum is commonly used as a supplement in cell culture media to support the growth and maintenance of various cell types.
Sourced in Italy
The Scrambled Shocker is a laboratory device designed to deliver a controlled electrical stimulation. It generates a scrambled electric current that can be applied to various experimental samples or subjects.
The ECT unit (Model 57800) is a laboratory equipment designed to measure Evoked Cortical Responses (ECR). It records electrical signals from the surface of the brain in response to stimuli. The device is capable of generating and delivering various types of stimuli to elicit these responses.
Sourced in United States, Japan, United Kingdom, Austria, Germany, Czechia, Belgium, Denmark, Canada
SPSS version 22.0 is a statistical software package developed by IBM. It is designed to analyze and manipulate data for research and business purposes. The software provides a range of statistical analysis tools and techniques, including regression analysis, hypothesis testing, and data visualization.
More about "Electroconvulsive Therapy"
Electroconvulsive Therapy (ECT) is a well-established medical procedure that involves the administration of controlled electric currents to the brain, inducing a therapeutic seizure.
This innovative treatment is primarily used to manage severe mental health conditions, such as major depressive disorder, bipolar disorder, and treatment-resistant schizophrenia.
PubCompare.ai's cutting-edge AI-powered platform helps researchers and clinicians locate the latest ECT protocols from a vast array of literature, preprints, and patents.
By utilizing intelligent comparison algorithms, the platform identifies the most effective and efficient ECT protocols and products, streamlining the research process and optimizing patient outcomes.
This advanced technology enables researchers to stay at the forefront of ECT advancements, exploring new methods like the FBS (Fetal Bovine Serum) and Model 7800 ECT units, which may incorporate Penicillin, Streptomycin, GlutaMAX, and Bovine serum albumin or Horse serum to enhance the safety and efficacy of the procedure.
Through the use of SPSS version 22.0 and other advanced statistical tools, researchers can analyze the data collected from these ECT studies, identifying patterns and trends that may lead to the development of improved 'Scrambled shocker' techniques and the next generation of ECT units (e.g., Model 57800).
By harnessing the power of PubCompare.ai, researchers and clinicians can accelerate the pace of innovation in this critical field of mental health treatment, ultimately improving the lives of patients struggling with debilitating conditions.
This innovative treatment is primarily used to manage severe mental health conditions, such as major depressive disorder, bipolar disorder, and treatment-resistant schizophrenia.
PubCompare.ai's cutting-edge AI-powered platform helps researchers and clinicians locate the latest ECT protocols from a vast array of literature, preprints, and patents.
By utilizing intelligent comparison algorithms, the platform identifies the most effective and efficient ECT protocols and products, streamlining the research process and optimizing patient outcomes.
This advanced technology enables researchers to stay at the forefront of ECT advancements, exploring new methods like the FBS (Fetal Bovine Serum) and Model 7800 ECT units, which may incorporate Penicillin, Streptomycin, GlutaMAX, and Bovine serum albumin or Horse serum to enhance the safety and efficacy of the procedure.
Through the use of SPSS version 22.0 and other advanced statistical tools, researchers can analyze the data collected from these ECT studies, identifying patterns and trends that may lead to the development of improved 'Scrambled shocker' techniques and the next generation of ECT units (e.g., Model 57800).
By harnessing the power of PubCompare.ai, researchers and clinicians can accelerate the pace of innovation in this critical field of mental health treatment, ultimately improving the lives of patients struggling with debilitating conditions.